KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: In-licencing of Phase II-ready molecule - presentation-NRT.AX, page-17

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,137 Posts.
    lightbulb Created with Sketch. 383
    This is a good change for Novogen IMO. While I agree we are now going to be burning cash at a higher rate we also get a PII ready GBM drug that I expect they would somehow bring the Trilexium GBM drug features to influence! Otherwise it would be a waste of that work done on our already well tested GBM that does cross the BBB. Buying a company that has all the functions, you'd hope, to manage this PII test is smart as it allows us to continue with Cantrixil without stressing the science teams...

    I like this purchase!

    Wonder if Eleanor is still with us?? from ann June 4, 2015:
     
    Eleanor Ager PhD, Novogen GBM Program Manager, said, "TRXE-009 shows remarkably potent killing in the test tube against a wide range of cancer types, but it has been its particularly potent activity against brain cancers including glioblastoma and DIPG that has marked it as a potential treatment of primary brain cancers in both adults in children. These are tumors that show high levels of resistance to standard of care drugs, so even if it was possible to get those drugs into the brain, they may not offer clinical benefit."
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.